Our popular case-based “Mastering the Aortic Valve” CME event returns to New York City in the heart of holiday season with its most ambitious agenda to date.
Results of a large cohort study reveal why our cardiac surgeons favor reimplantation for most patients, even those with severe aortic regurgitation and a significantly enlarged aortic root.
Until a durable, anticoagulation-free valve prosthesis is developed, preservation of a well-functioning bicuspid aortic valve may be the best course in the setting of isolated ascending aortic replacement, a new study suggests.
Outcomes appear to diverge over time between patients with bicuspid versus tricuspid valves, raising concern over the use of bicuspid valve reimplantation in the absence of extensive surgical expertise.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The new update to definitions of clinical endpoints for aortic valve disease trials gives more focus to secondary outcomes, composite safety and efficacy measures, and quality-of-life metrics.
Three of our valve disease experts reflect on key changes and developments related to aortic valve disease in the new guideline update.
Both of this year’s lifetime honors in echocardiography went to Cleveland Clinic caregivers — Dr. William Stewart won the physician award and Margaret (Koko) Park earned the sonographer prize.
Congenital bicuspid aortic valve repair carries a low risk of death, stroke and re operation, and prevents the need for lifelong anti-coagulation required for a prosthetic valve.